Document text
Principal Investigator: Adrian McDermott
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2021
Award: $8,027,794
Funding agency: National Institute of Allergy and Infectious Diseases
The Vaccine Immunology Program (formerly NIAID Vaccine Immune T cell and Antibody Laboratory Core/Immunology Core Laboratory) is responsible for the end point analyses of clinical vaccine, therapeutic and prevention trials carried out by the Vaccine Research Center and collaborates with intramural and extramural investigators. In addition, the VIP investigates basic B and T cell immunobiology to elucidate the mechanisms that inform the discovery and development of vaccines for public health, including HIV, Influenza, Ebola, Zika, Malaria, TB, SARS-CoV-2 plus other emerging and re-emerging infectious diseases, and develops sophisticated analyses that supports in-depth investigation of clinical vaccine trials, including highly qualified clinical assays for use in IND submissions and product licensure purposes.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Antibodies><Assay><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bioassay><Biologic Assays><Biological Assay><COVID-19 virus><COVID19 virus><Clinical><CoV-2><CoV2><Development><EXTMR><Ebola><Emerging Communicable Diseases><Emerging Infectious Diseases><Extramural><Extramural Activities><Goals><Grippe><HIV><Human Immunodeficiency Viruses><Immune><Immunes><Immunobiology><Immunology><Immunophysiology><Influenza><Investigators><LAV-HTLV-III><Laboratories><Licensure><Lymphadenopathy-Associated Virus><Malaria><NIAID><National Institute of Allergy and Infectious Disease><Paludism><Plasmodium Infections><Prevention trial><Public Health><Research Personnel><Researchers><SARS corona virus 2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><T-Cells><T-Lymphocyte><Therapeutic Trials><Vaccine Clinical Trial><Vaccine Research><Vaccines><Virus-HIV><Wuhan coronavirus><ZIKA><clinical investigation><coronavirus disease 2019 virus><develop a vaccine><development of a vaccine><developmental><hCoV19><nCoV2><programs><thymus derived lymphocyte><vaccine development><vaccine formulation>